Project Updates

Applied Gene and Cell Therapy Center

Credit: Lee & Associates / PR Newswire

Location: Sharon, Ohio US
Project type: Gene and cell therapy centre
Initial investment: $60m
Expected opening: 2025

Cincinnati Children’s Hospital Medical Center’s (CCHMC) new Applied Gene and Cell Therapy Centre will be developed by renovating an existing building to produce gene, cell, and immunotherapy products for clinical trials.

Kyowa Kirin Biologics Manufacturing Plant

Credit: Kyowa Kirin

Location: North Carolina, US
Project type: Manufacturing facility
Estimated investment: $530m
Construction Started: H2 2024 

Japanese pharma Kyowa Kirin’s biologics manufacturing facility will produce cutting-edge biologic therapies, such as next-generation antibodies, for the company’s upcoming clinical trials and future commercial purposes.

The Paul and Diane Manning Institute

Credit: UVA

Location: Virginia, US
Project type: Research institute
Estimated investment: $350m
Construction Started: December 2023

The University of Virginia’s (UVA) Paul and Diane Manning Institute of Biotechnology will expedite research in areas including cell therapy, gene therapy, nanotechnology and drug delivery, for the development of new medical treatments.

Go to article: Home | Left in limbo: When pharma halts rare disease researchGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: FaravelliGo to article: In DepthGo to article: Left in limbo: When pharma halts rare disease research Go to article: Capturing the genAI boom for drug developmentGo to article: Too much data: a burden or a blessing? Go to article: South Korea seeks to accelerate drug reimbursement administration process Go to article: Sponsors must take on FDA’s diversity guidance to improve community trust Go to article: DelSiTech Company InsightGo to article: Thematic Take: CybersecurityGo to article: Thematic Take: contentsGo to article: Foreword: Cybersecurity in the age of AI Go to article: Navigating the AI-driven cybersecurity landscapeGo to article: Key trends impacting cybersecurity Go to article: Timeline: a history of cybersecurity Go to article: Explainer: The most common types of cyberattacks Go to article: The impact of cybersecurity on healthcareGo to article: Case studies: cybersecurity in healthcare Go to article: Leading cybersecurity adopters and providers in healthcareGo to article: AI attacks now ‘the main cybersecurity concern’ for businesses across sectors Go to article: The state of cybersecurity: AI and geopolitics mean a bigger threat than ever Go to article: Companies’ own AI applications are ‘a huge cybersecurity problem’ Go to article: How healthcare cybercrime is predicted to escalate Go to article: The lasting impacts of the pandemic on cybersecurity in healthcare Go to article: Cyberattacks on healthcare: Russia’s tool for mass disruption Go to article: Traceability technologies tighten supply chain fakery Go to article: Deal activity related to cybersecurity in the pharma industry since 2021 Go to article: Regulators must protect the cybersecurity market from a private equity takeover Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: XylemGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue